Alto Neuroscience ANRO Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $45.62M-2.9% | $47M+55.1% | ||
| $20.75M-4.0% | $21.61M+187% | ||
| $66.36M-3.3% | $68.61M+81.5% | ||
| -$66.36M+3.3% | -$68.61M-81.5% | ||
| $2.47M+79.6% | $1.38M+0.4% | ||
| $3.13M-56.5% | $7.18M+377% | ||
| -$63.24M-2.9% | -$61.43M-69.2% | ||
| -$2.18+14.2% | -$2.54+73.9% | ||
| -$65.74M+3.4% | -$68.04M-81.9% | ||
| -$66.36M+3.3% | -$68.61M-81.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Alto Neuroscience profitable?
- Alto Neuroscience is not currently profitable: it reported a net loss of $74.3M over the trailing twelve months.
- What is Alto Neuroscience's earnings per share?
- Alto Neuroscience's diluted EPS over the trailing twelve months is $-2.42.
- Where does Alto Neuroscience's income statement data come from?
- Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.